Trial results
AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
According to the results reported on ClinicalTrials.gov, this trial (NCT03706040) enrolled 172 adults with atopic eczema (eczema). In the first phase of the trial (the first 16 weeks), participants were randomly assigned to receive either a placebo (an inactive treatment), a 150 mg dose of a medicine called risankizumab, or a 300 mg dose of risankizumab. In the second phase (weeks 16 to 52), participants continued or switched treatments depending on which group they had been in. The trial was primarily measuring how many people's eczema improved significantly — specifically, how many achieved at least a 75% reduction in a standard eczema scoring system called the EASI (a score from 0 to 72, where higher numbers mean worse eczema). The reported data shows that at week 16, around 11.8% of those on placebo, 24.6% on the 150 mg dose, and 21.7% on the 300 mg dose reached that 75% improvement mark. For a secondary measure looking at how a doctor rated overall eczema severity (on a scale of 0 to 4), 5.9% of the placebo group, 14.5% on 150 mg, and 5.8% on 300 mg reached a score of 0 or 1 (meaning "clear" or "almost clear") with at least a 2-point improvement. When it came to participants rating their worst itch in the past 24 hours, 0% of the placebo group, 13.6% on 150 mg, and 15.2% on 300 mg reported a reduction of 4 or more points on an 11-point scale. The reported average change in EASI score at week 16 was a reduction of about 28.5% for placebo, 38.9% for the 150 mg group, and 45.4% for the 300 mg group. In the second phase, the reported data shows further changes in EASI scores and response rates across the different continuation and switch groups at weeks 28 and 52, though the numbers varied considerably between subgroups, some of which were quite small. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.
View full results on ClinicalTrials.gov ↗ · Read the linked publication on PubMed (PMID 36588137) ↗
These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.
Phase 2 Eczema Trial, Completed
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- You are 18 years old or older (or at least 12 years old, depending on where the trial is taking place and if it is allowed in your area)
- You have been diagnosed with atopic dermatitis (eczema) and your symptoms started at least 2 years before joining the trial, and your diagnosis meets a specific set of medical criteria (confirm with trial site)
- Your atopic dermatitis is considered moderate to severe at the time of your first trial visit
- You have tried steroid creams or other prescribed skin creams in the past but they did not work well enough for you, or you are medically unable to use those treatments
Who may not be able to join:
- You have previously received a biologic medication (a type of specialist drug that targets the immune system) or a JAK inhibitor (another type of specialist medication) at any point in the past
- You are currently using any systemic (whole-body) treatments, biologic treatments, prescribed skin creams, or light therapy for your atopic dermatitis at the time of joining
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: ABBVIE INC., AbbVie
Australian sites
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
6 site(s) in Australia. Confirm current status and contact details directly with the trial site.
Primary endpoints
Percentage of Participants Achieving At Least a 75% Reduction From Baseline in Eczema Area and Severity Index (EASI 75) at Week 16
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.